FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number: 3235-0104							
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

	01 3000		the investment Company Act of 19							
Chivukula Pad	Date of Event Requiring Stater Month/Day/Yea 01/01/2019	nent	3. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Ltd. [ARCT]							
(Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS LTD.			Relationship of Reporting Perso (Check all applicable) Director	10% Owne	r (Moi	5. If Amendment, Date of Original Filed (Month/Day/Year)				
10628 SCIENCE CENTER DRIVE, SUITE 250			X Officer (give title below) Chief Scientific Office	Other (spective) below) er & COO	6. In	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) SAN DIEGO CA 92121						Form filed by Reporting Po	y More than One erson			
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			eneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Ordinary Shares			732,548(1)(2)	D						
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	or Indirect (I) (Instr. 5)				
STOCK OPTION (right to purchase)(1)(2)	(3)	08/23/2028	Ordinary Shares	80,000	8	D				

Explanation of Responses:

- 1. The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
- $2.\ 183{,}137$ of such shares are subject to repurchase by the Issuer.
- $3. \ Vesting over a period of four years from August 24, 2018, with 25\% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter.$

/s/ Padmanabh Chivukula

01/02/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.